We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
IQVIA (IQV) Down 1.1% Since Last Earnings Report: Can It Rebound?
Read MoreHide Full Article
It has been about a month since the last earnings report for IQVIA Holdings (IQV - Free Report) . Shares have lost about 1.1% in that time frame, underperforming the S&P 500.
But investors have to be wondering, will the recent negative trend continue leading up to its next earnings release, or is IQVIA due for a breakout? Well, first let's take a quick look at the most recent earnings report in order to get a better handle on the recent catalysts for IQVIA Holdings Inc. before we dive into how investors and analysts have reacted as of late.
IQVIA Surpasses Q2 Earnings Estimates
IQVIA has reported impressive second-quarter 2025 results, wherein earnings and revenues beat the Zacks Consensus Estimate.
Adjusted earnings were $2.81 per share, beating the Zacks Consensus Estimate by 1.8% and rising 6.4% on a year-over-year basis. Total revenues of $4 billion surpassed the consensus estimate by 1.5% and grew 5.3% from the year-ago quarter.
IQVIA’s Quarterly Details
The Research and Development segment’s revenues were $2.2 billion, rising 2.5% from the year-ago quarter and 1.3% on a constant-currency basis. The metric met our estimate.
Revenues from the Technology and Analytics segment were $1.6 billion, increasing 8.9% from the year-ago quarter and 6.8% on a constant-currency basis. The metric met our estimated figure.
Contract Sales and Medical Solutions revenues increased 9.3% on a year-over-year basis to $188 million and increased 6.4% on a constant-currency basis. The metric surpassed our estimation of $181.9 million.
Adjusted EBITDA for the second quarter of 2025 was $910 million, up 2.6% from the year-ago quarter and beating our projection of $899.4 million.
The company exited the quarter with cash and cash equivalents of $2 billion compared with $1.7 billion in the preceding quarter. Long-term debt (less current portion) was $15.5 billion compared with $13.1 billion at the end of the first quarter of 2025.
Net cash generated from operating activities was $443 million and the capital expenditure for the quarter was $151 million. The company generated a free cash flow of $292 million in the quarter.
IQV’s 2025 Guidance
For 2025, IQVIA has updated its revenue guidance to $16.10-$16.30 billion from the $16.00-$16.40 billion provided in the preceding quarter.
IQVIA’s adjusted EBITDA view was lowered to $3.75-$3.825 billion from the preceding quarter’s view of $3.76-$3.88 billion.
The company has updated its adjusted EPS guidance to $11.75-$12.05 from the preceding quarter’s view of $11.70-$12.10.
How Have Estimates Been Moving Since Then?
In the past month, investors have witnessed a downward trend in estimates revision.
VGM Scores
At this time, IQVIA has a average Growth Score of C, though it is lagging a lot on the Momentum Score front with an F. However, the stock has a score of B on the value side, putting it in the top 40% for value investors.
Overall, the stock has an aggregate VGM Score of C. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. Notably, IQVIA has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
IQVIA (IQV) Down 1.1% Since Last Earnings Report: Can It Rebound?
It has been about a month since the last earnings report for IQVIA Holdings (IQV - Free Report) . Shares have lost about 1.1% in that time frame, underperforming the S&P 500.
But investors have to be wondering, will the recent negative trend continue leading up to its next earnings release, or is IQVIA due for a breakout? Well, first let's take a quick look at the most recent earnings report in order to get a better handle on the recent catalysts for IQVIA Holdings Inc. before we dive into how investors and analysts have reacted as of late.
IQVIA Surpasses Q2 Earnings Estimates
IQVIA has reported impressive second-quarter 2025 results, wherein earnings and revenues beat the Zacks Consensus Estimate.
Adjusted earnings were $2.81 per share, beating the Zacks Consensus Estimate by 1.8% and rising 6.4% on a year-over-year basis. Total revenues of $4 billion surpassed the consensus estimate by 1.5% and grew 5.3% from the year-ago quarter.
IQVIA’s Quarterly Details
The Research and Development segment’s revenues were $2.2 billion, rising 2.5% from the year-ago quarter and 1.3% on a constant-currency basis. The metric met our estimate.
Revenues from the Technology and Analytics segment were $1.6 billion, increasing 8.9% from the year-ago quarter and 6.8% on a constant-currency basis. The metric met our estimated figure.
Contract Sales and Medical Solutions revenues increased 9.3% on a year-over-year basis to $188 million and increased 6.4% on a constant-currency basis. The metric surpassed our estimation of $181.9 million.
Adjusted EBITDA for the second quarter of 2025 was $910 million, up 2.6% from the year-ago quarter and beating our projection of $899.4 million.
The company exited the quarter with cash and cash equivalents of $2 billion compared with $1.7 billion in the preceding quarter. Long-term debt (less current portion) was $15.5 billion compared with $13.1 billion at the end of the first quarter of 2025.
Net cash generated from operating activities was $443 million and the capital expenditure for the quarter was $151 million. The company generated a free cash flow of $292 million in the quarter.
IQV’s 2025 Guidance
For 2025, IQVIA has updated its revenue guidance to $16.10-$16.30 billion from the $16.00-$16.40 billion provided in the preceding quarter.
IQVIA’s adjusted EBITDA view was lowered to $3.75-$3.825 billion from the preceding quarter’s view of $3.76-$3.88 billion.
The company has updated its adjusted EPS guidance to $11.75-$12.05 from the preceding quarter’s view of $11.70-$12.10.
How Have Estimates Been Moving Since Then?
In the past month, investors have witnessed a downward trend in estimates revision.
VGM Scores
At this time, IQVIA has a average Growth Score of C, though it is lagging a lot on the Momentum Score front with an F. However, the stock has a score of B on the value side, putting it in the top 40% for value investors.
Overall, the stock has an aggregate VGM Score of C. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. Notably, IQVIA has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.